|  |  |
| --- | --- |
| [Hospital letter head]Local lead investigator: [#local\_lead] |  |



Date

Dear Dr

Re: *<Patient Name and Address>*.

 …………………………………….

 …………………………………….

**ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections MREC No 13/SC/0149. UKCRN ID 14152**

**CI: Dr Calum Semple, University of Liverpool.**

I am writing to inform you that your patient has been enrolled into the above research study.

The purpose of the study is to develop an understanding of disease processes in patients with emerging severe acute respiratory infections. This is needed in order to identify elements such as risk factors for severe illness, and in order for new treatments to be developed.

The study, will require repeat sampling of blood, and when possible, urine, stools, sputum and respiratory tract specimens, that will not immediately benefit the patient. The samples need to be taken in addition to those required for medical management. The study will require analysis of host genome, which may reveal other information about disease susceptibility or other aspects of health status.

Blood and pathogen samples will be taken regularly during the first 100 days of illness, followed by a convalescent visit and blood sample at 3 and 6 months post recruitment.

If you have any questions regarding any of the above, please feel free to contact me on *<contact phone number>.*

Please find the enclosed information sheet for your information.

Yours sincerely

<*Researcher`s Name, Title*>